Comparative Pharmacology

Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFTAZIDIME.

Peer-Reviewed Evidence

Differential Analysis

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER vs CEFTAZIDIME

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

Cephalosporin Antibiotic

Category C

CEFTAZIDIME

Cephalosporin Antibiotic

Category A/B

Head-to-Head

Clinical Matrix

Mechanism of Action

Ceftizoxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.

Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.

Clinical Dosing

1-2 g IV every 8-12 hours; maximum 12 g/day

1-2 g IV every 8 hours

Direct Interaction

None Documented

Half-Life

1.5–2 hours in normal renal function; extends to 20–30 hours in ESRD. Dose adjustment required for CrCl <50 mL/min.

Other Significant Interactions

Clinical Note

moderate

Ceftazidime + Probenecid

"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."

Clinical Note

moderate

Ceftazidime + Picosulfuric acid

"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."

Clinical Note

moderate

Warfarin + Ceftazidime

"Warfarin may increase the anticoagulant activities of Ceftazidime."

Clinical Note

moderate

Phenprocoumon + Ceftazidime